Immuno-Oncology | Specialty

Dr. Patrick Borgen on the Future of Breast Cancer Treatment

October 1st 2014

The Ongoing Debate Over Mammography-Screening Matters

October 1st 2014

Prophylactic Double Mastectomy-Does it Make a Difference?

October 1st 2014

ATEMPT Trial at Dana-Farber Cancer Institute

October 1st 2014

BRCA Screening Recommendations by Geneticist Mary-Claire King

October 1st 2014

Latest News & Insight: October 1, 2014

October 1st 2014

Dr. Saab on a Phase II Study of the Oncolytic Virus Reolysin for Pancreatic Cancer

September 30th 2014

Tanios Bekaii-Saab, MD, discusses the results of a phase II study of the oncolytic virus reolysin in the first-line treatment metastatic adenocarcinoma of the pancreas.

Durable Responses Observed with Nivolumab in Previously Treated mRCC

September 30th 2014

Durable responses were obtained with the immune checkpoint inhibitor nivolumab, with a manageable safety profile, in a phase II dose-ranging trial conducted in patients with previously treated metastatic renal cell carcinoma (mRCC).

Dr. Motzer on a Phase II Trial of Nivolumab for mRCC

September 30th 2014

Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of a phase II study of nivolumab for the treatment of patients with clear cell metastatic renal cell carcinoma.

Pembrolizumab Shows Promise in Advanced Gastric Cancer

September 29th 2014

In patients with advanced gastric cancer expressing PD-L1, pembrolizumab (Keytruda) has robust antitumor activity and an acceptable safety profile

Dr. Weber on Nivolumab Versus Chemotherapy in Advanced Melanoma

September 29th 2014

Jeffrey S. Weber, MD, PhD, discusses the results of a phase III study of nivolumab compared with investigator's choice chemotherapy for the treatment of patients with advanced melanoma after prior anti-CTLA-4 therapy.

Nivolumab Beats Chemotherapy as Second-Line Treatment for Advanced Melanoma

September 29th 2014

Treatment with nivolumab (Opdivo) demonstrated superior objective response rates (ORR) and longer durations of response compared with chemotherapy in a phase III trial of patients with previously treated advanced metastatic melanoma, reported Jeffrey Weber, MD, at the 2014 ESMO Congress.

Pembrolizumab Yields Durable Responses in Advanced NSCLC

September 28th 2014

Almost 60% of patients with advanced non–small cell lung cancer experienced tumor shrinkage when treated with the PD-L1 inhibitor pembrolizumab.

Dr. Kluger on a Phase I Trial of Concurrent Nivolumab and Ipilimumab

September 28th 2014

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the results from a phase I trial of nivolumab and ipilimumab for the treatment of patients with advanced melanoma.

Peter Emtage on the Combination of MEDI4736 and Tremelimumab for NSCLC

September 27th 2014

Peter Emtage, discusses a phase I open-label study evaluating the safety and tolerability of MEDI4736 in combination with tremelimumab for the treatment of patients with advanced non-small cell lung cancer.

FDA Grants Priority Review to Nivolumab in Melanoma

September 26th 2014

The FDA has assigned a priority review designation to the PD-1 inhibitor nivolumab (Opdivo) as a treatment for pretreated patients with advanced melanoma.

UCLA Researcher Provides Insight Into the Impact of Pembrolizumab in Melanoma

September 13th 2014

To gain further insight into the approval of pembrolizumab, OncLive interviewed John Glaspy, MD, MPH, from the Jonsson Comprehensive Cancer Center at UCLA, where research into the novel drug was conducted.

Rosenberg Sees New Milestone in Latest CAR Findings

September 9th 2014

Steven A. Rosenberg, MD, PhD, discusses the implications of responses to the CAR T-cell therapy KTE-C19, particularly among patients with chemotherapy-refractory diffuse large B-cell lymphomas.

Hurvitz Discusses PIK3CA Mutations, pCR, CDK4/6 Inhibitors, and Immunotherapies in Breast Cancer

September 9th 2014

Sara Hurvitz, MD, highlights key points on the PIK3CA mutation, and addresses several other key topics in the field of breast cancer.

Dr. Andtbacka on T-VEC Plus Ipilimumab in Unresected Melanoma

September 8th 2014

Robert H. I. Andtbacka, MD, CM, from Intermountain Healthcare and Huntsman Cancer Institute, discusses the safety and efficacy of T-VEC in combination with ipilimumab in patients with previously untreated, unresected stage IIIB-IV melanoma.